Skip to main content
Fig. 1 | BMC Ophthalmology

Fig. 1

From: Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab

Fig. 1

Diagram summarising the timeline of data collection in this study. All patients had an initial loading phase of 3 monthly injections of RBZ (stage 1) followed by a PRN treatment schedule with RBZ (stage 2) which was on average 129 (±86) weeks. After switch, patients had 3 loading monthly injections of AFL (stage 3) followed by PRN AFL (stage 4). The mean time for AFL PRN treatment was 85 (±18) weeks. Data was collected at baseline (1) and 4-week review post RBZ loading (2). Further data was collected at switch to AFL (3), 4-week review post AFL loading (4) and > 12 months after switch (5)

Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us